IVVD on XNAS, Health Care, Invivyd, Inc., job postings
Measures activity, not value. Not investment advice.
Revenue up 21% to $60.7M but shares fell 83% in 12 months with a $130.3M loss.
BadShort interest at 12% of shares, with 9.7 days to cover
GoodInstitutional holders rose from 124 to 134 in the quarter
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 7 Jan 2027 (an estimate: a year ago it reported on 8 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $15.4M, net loss $33.5M.
31 Dec 2021RevenueNet incomeNet losstallest bar $100.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$15.4M
-$33.5M
30 Jun 2026
$14.3M
-$44.4M
31 Mar 2026
$13.7M
-$41.4M
31 Dec 2025
$17.2M
-$11.1M
30 Sep 2025
$13.1M
-$10.5M
30 Jun 2025
$11.8M
-$14.7M
31 Mar 2025
$11.3M
-$16.3M
31 Dec 2024
$13.8M
-$18.4M
30 Sep 2024
$9.3M
-$60.7M
30 Jun 2024
$2.3M
-$47.2M
31 Mar 2024
$0
-$43.5M
31 Dec 2023
$0
-$73.7M
30 Sep 2023
$0
-$39.4M
30 Jun 2023
$0
-$50.2M
31 Mar 2023
–
-$35.3M
31 Dec 2022
–
-$44.6M
30 Sep 2022
–
-$45.1M
30 Jun 2022
–
-$51.0M
31 Mar 2022
–
-$100.7M
31 Dec 2021
–
-$83.0M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$60.7M
$50.0M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+21%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$130.3M
-$59.9M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$0.37
-$0.47
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-224%
-124%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
-215%
-120%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-107%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$126.4M
$85.0M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
$1.0B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
$915.0M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$0.51
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
2.0
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.81
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+8.1%
134 13F filers vs 124
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
74%
218.5M shares held by 13F filers (30 Sep 2026) of 295.6M outstanding (29 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
12%
36.2M shares sold short (30 Oct 2026) of 295.6M outstanding (29 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
9.7
36.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-2.3%
37.0M shares sold short in the report before, 36.2M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
44%
44% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 49%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
12
Tracked since 20 Nov 2026
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
Tracking started 20 Nov 2026; the change shows after 30 days.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+18%
$15.4M vs $13.1M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$460K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
13
13 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
13×
13 articles in the last 7 days; its usual week has 1.
Price $0.41 on 20 Nov 2026, -83% over 12 months (12-month range $0.41 to $2.88)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $436K in the last 12 months (the 12 months before: -$848K).Revenue per quarter. Revenue $15.4M in the latest quarter, +18% on a year earlier.Capital spending per quarter. Capital spending $585K in the latest quarter.Institutional holders (13F filers). 134 13F filers reported holding it in the latest 13F quarter, +79% on a year earlier.Lobbying spend. Lobbying spend: $460K published in the last 12 months (none in the 12 months before).
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.
Quarter ended 30 Jun 2023: $0; public on 15 Aug 2024
Quarter ended 30 Sep 2023: $0; public on 15 Nov 2024
Quarter ended 31 Dec 2023: $0; public on 21 Mar 2025
Quarter ended 31 Mar 2024: $0; public on 16 May 2025
Quarter ended 30 Jun 2024: $2.3M; public on 15 Aug 2024
Quarter ended 30 Sep 2024: $9.3M; public on 15 Nov 2024
Quarter ended 31 Dec 2024: $13.8M; public on 21 Mar 2025
Quarter ended 31 Mar 2025: $11.3M; public on 16 May 2025
Quarter ended 30 Jun 2025: $11.8M, +421% on a year earlier; public on 15 Aug 2025
Quarter ended 30 Sep 2025: $13.1M, +41% on a year earlier; public on 7 Nov 2025
Quarter ended 31 Dec 2025: $17.2M, +25% on a year earlier; public on 6 Mar 2026
Quarter ended 31 Mar 2026: $13.7M, +22% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $14.3M, +21% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $15.4M, +18% on a year earlier; public on 17 Nov 2026
Capital spending per quarter
Quarter ended 30 Sep 2021: $0; public on 11 Nov 2022
Quarter ended 31 Dec 2021: $84K; public on 1 Apr 2022
Quarter ended 31 Mar 2022: $0; public on 12 May 2023
Quarter ended 30 Sep 2022: $477K; public on 11 Nov 2022
Quarter ended 31 Dec 2022: $1.2M, +1342% on a year earlier; public on 24 Mar 2023
Quarter ended 30 Sep 2023: $0, -100% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $0, -100% on a year earlier; public on 29 Mar 2024
Quarter ended 31 Mar 2024: $140K; public on 10 May 2024
Quarter ended 30 Sep 2024: $5K; public on 15 Nov 2024
Quarter ended 31 Mar 2025: $144K, +2.9% on a year earlier; public on 16 May 2025
Quarter ended 30 Jun 2025: $11K; public on 15 Aug 2025
Quarter ended 31 Mar 2026: $726K, +404% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $510K, +4536% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $585K; public on 17 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 69; public on 14 Feb 2022
31 Mar 2022 report: 70; public on 16 May 2022
30 Jun 2022 report: 72; public on 15 Aug 2022
30 Sep 2022 report: 70; public on 14 Nov 2022
31 Dec 2022 report: 74; public on 14 Feb 2023
31 Mar 2023 report: 68; public on 15 May 2023
30 Jun 2023 report: 55; public on 14 Aug 2023
30 Sep 2023 report: 55; public on 14 Nov 2023
31 Dec 2023 report: 56; public on 14 Feb 2024
31 Mar 2024 report: 84; public on 15 May 2024
30 Jun 2024 report: 76; public on 14 Aug 2024
30 Sep 2024 report: 74; public on 14 Nov 2024
31 Dec 2024 report: 77; public on 14 Feb 2025
31 Mar 2025 report: 77; public on 15 May 2025
30 Jun 2025 report: 65; public on 14 Aug 2025
30 Sep 2025 report: 75; public on 14 Nov 2025
31 Dec 2025 report: 110; public on 17 Feb 2026
31 Mar 2026 report: 136; public on 15 May 2026
30 Jun 2026 report: 124; public on 14 Aug 2026
30 Sep 2026 report: 134; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2022: $10K published
Quarter from 1 Jul 2022: $120K published
Quarter from 1 Oct 2022: $120K published
Quarter from 1 Jan 2023: $120K published
Quarter from 1 Apr 2023: $120K published
Quarter from 1 Jul 2023: $120K published
Quarter from 1 Oct 2023: $120K published
Quarter from 1 Jan 2024: $120K published
Quarter from 1 Apr 2024: $120K published
Quarter from 1 Jul 2024: $87K published
Quarter from 1 Oct 2024: $6K published
Quarter from 1 Jan 2026: $20K published
Quarter from 1 Apr 2026: $80K published
Quarter from 1 Jul 2026: $180K published
Quarter from 1 Oct 2026: $180K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is 13F holders (funds reporting the stock) at 134 (30 Sep 2026), 1.8× its normal reading; higher than 95% of its own history.
12 open postings; careers site tracked since 20 Nov 2026. Most in Sales & business development 58%, Marketing & communications 17%, Program & project management 17%, Legal, policy & compliance 8%.
Reported lobbying spend: $180K in Q3 2026, $180K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for the Public Health Social Services Emergency Fund (PHSSEF)- Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield; Education and awareHealth issues
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for the Public Health Social Services Emergency Fund (PHSSEF) - Strategic National Stockpile (SNS); Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield; Education and awarDIS, Budget, Health issues
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for the Public Health Social Services Emergency Fund (PHSSEF)- Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield; Education and awareDIS, Budget, Health issues
The Mcmanus Groupfor Invivyd (Formerly Known As Adagio Therapeutics))
Education and awareness related to COVID-19 therapeutics. Issues related to H.R.4421 Preparing for All Hazards and Pathogens Reauthorization Act and S.2333 - Pandemic and All-Hazards Preparedness and Response ActHealth issues
Two or more unrelated kinds of records unusual within 30 days
17 Feb 2026confirmed
Confirmed across sources Institutional holdings and Short interest and volume
Invivyd(IVVD): had 21.4M shares sold short in the 15 Jan 2026 report, 3.4× the same report last year, while it saw 46 13F filers open a new position in the quarter ended 31 Dec 2025, 5.1× the same quarter last year. Two unrelated kinds of activity within 28 days.
Short interest and volume: Short interest spike, became public on 28 Jan 2026
Institutional holdings: Many funds opening a new position, became public on 17 Feb 2026
Short interest and volume: Short interest spike, became public on 11 Feb 2026
Short interest and volume: Short interest spike, became public on 26 Feb 2026
The 15 Jan 2026 report against the 24 reports before it.
this reportearliernormal: 7.1MSee the evidence (4 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2026
Invivyd had 21.4M shares sold short in the 15 Jan 2026 report, 3.4× the same report last year.
This period
21.4M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
7.1M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+6.0
Same report last year
6.3M
History used
1,218 days
the 15 Jan 2026 report24 earlier reportsnormal: 7.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 17 Feb 2026
Invivyd saw 46 13F filers open a new position in the quarter ended 31 Dec 2025, 5.1× the same quarter last year.
This period
46 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
15.5
Typical spread (median absolute deviation)
5
How far from its usual level
+4.1
Same quarter last year
9
History used
1,553 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 15.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Feb 2026
Invivyd had 22.3M shares sold short in the 30 Jan 2026 report, 3.4× the same report last year.
This period
22.3M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
7.4M
Typical spread (median absolute deviation)
2.0M
How far from its usual level
+4.9
Same report last year
6.6M
History used
1,233 days
the 30 Jan 2026 report24 earlier reportsnormal: 7.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
Invivyd had 22.7M shares sold short in the 13 Feb 2026 report, 2.7× the same report last year.
This period
22.7M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
7.7M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+3.8
Same report last year
8.5M
History used
1,247 days
the 13 Feb 2026 report24 earlier reportsnormal: 7.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
21 May 2024confirmed
Confirmed across sources Institutional holdings and Lobbying and Short interest and volume
Invivyd(IVVD): saw 29 13F filers open a new position in the quarter ended 31 Mar 2024, 4.8× the same quarter last year; it also lobbying on a new issue; and it had 7.9M shares sold short in the 15 Aug 2024 report, 3.3× the same report last year. Three unrelated kinds of activity within 154 days.
Short interest and volume: Short interest spike, became public on 25 Apr 2024
Short interest and volume: Short interest spike, became public on 10 May 2024
Institutional holdings: Many funds opening a new position, became public on 15 May 2024
Short interest and volume: Short interest spike, became public on 25 May 2024
Short interest and volume: Short interest spike, became public on 12 Jun 2024
Short interest and volume: Short interest spike, became public on 27 Jun 2024
Short interest and volume: Short interest spike, became public on 11 Jul 2024
Lobbying: Lobbying on a new issue, became public on 18 Jul 2024
Short interest and volume: Short interest spike, became public on 25 Jul 2024
Short interest and volume: Short interest spike, became public on 10 Aug 2024
Short interest and volume: Short interest spike, became public on 27 Aug 2024
Short interest and volume: Short interest spike, became public on 12 Sep 2024
Short interest and volume: Short interest spike, became public on 25 Sep 2024
The quarter ended 31 Mar 2024 against the 8 quarters before it.
this quarterearliernormal: 10.5See the evidence (13 changes)
Short interest and volume: Short interest spike became public on 25 Apr 2024
Invivyd had 4.2M shares sold short in the 15 Apr 2024 report, 1.4× the same report last year.
This period
4.2M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
206K
How far from its usual level
+6.3
Same report last year
3.1M
History used
578 days
the 15 Apr 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 May 2024
Invivyd had 5.9M shares sold short in the 30 Apr 2024 report, 1.9× the same report last year.
This period
5.9M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
206K
How far from its usual level
+11.8
Same report last year
3.2M
History used
593 days
the 30 Apr 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2024
Invivyd saw 29 13F filers open a new position in the quarter ended 31 Mar 2024, 4.8× the same quarter last year.
This period
29 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
3.5
How far from its usual level
+3.6
Same quarter last year
6
History used
913 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 10.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 25 May 2024
Invivyd had 6.2M shares sold short in the 15 May 2024 report, 2.0× the same report last year.
This period
6.2M (the 15 May 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
206K
How far from its usual level
+12.7
Same report last year
3.1M
History used
608 days
the 15 May 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Jun 2024
Invivyd had 6.9M shares sold short in the 31 May 2024 report, 2.8× the same report last year.
This period
6.9M (the 31 May 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
206K
How far from its usual level
+15.0
Same report last year
2.5M
History used
624 days
the 31 May 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Jun 2024
Invivyd had 6.8M shares sold short in the 14 Jun 2024 report, 2.3× the same report last year.
This period
6.8M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
277K
How far from its usual level
+10.9
Same report last year
2.9M
History used
638 days
the 14 Jun 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Jul 2024
Invivyd had 7.1M shares sold short in the 28 Jun 2024 report, 3.2× the same report last year.
This period
7.1M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
277K
How far from its usual level
+11.6
Same report last year
2.2M
History used
652 days
the 28 Jun 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Lobbying: Lobbying on a new issue became public on 18 Jul 2024
Invivyd lobbying on a new issue.
New
['BUD', 'DIS']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6410097
Short interest and volume: Short interest spike became public on 25 Jul 2024
Invivyd had 7.6M shares sold short in the 15 Jul 2024 report, 3.6× the same report last year.
This period
7.6M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
358K
How far from its usual level
+10.0
Same report last year
2.1M
History used
669 days
the 15 Jul 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Aug 2024
Invivyd had 7.8M shares sold short in the 31 Jul 2024 report, 3.4× the same report last year.
This period
7.8M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
385K
How far from its usual level
+9.5
Same report last year
2.3M
History used
685 days
the 31 Jul 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2024
Invivyd had 7.9M shares sold short in the 15 Aug 2024 report, 3.3× the same report last year.
This period
7.9M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
415K
How far from its usual level
+9.0
Same report last year
2.4M
History used
700 days
the 15 Aug 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Sep 2024
Invivyd had 7.6M shares sold short in the 30 Aug 2024 report, 3.9× the same report last year.
This period
7.6M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
468K
How far from its usual level
+7.6
Same report last year
1.9M
History used
715 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2024
Invivyd had 7.4M shares sold short in the 13 Sep 2024 report, 3.5× the same report last year.
This period
7.4M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
673K
How far from its usual level
+4.8
Same report last year
2.1M
History used
729 days
the 13 Sep 2024 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
1 Sep 2026Filings change
filed a director or officer change (8-K item 5.02), its first in 90 days.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
had 22.7M shares sold short in the 13 Feb 2026 report, 2.7× the same report last year.
Same report last year: 8.5M; its normal report is 7.7M.
See the evidence
This period
22.7M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
7.7M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+3.8
Same report last year
8.5M
History used
1,247 days
the 13 Feb 2026 report24 earlier reportsnormal: 7.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 21.4M shares sold short in the 15 Jan 2026 report, 3.4× the same report last year, while it saw 46 13F filers open a new position in the quarter ended 31 Dec 2025, 5.1× the same quarter last year. Two unrelated kinds of activity within 28 days.
See the evidence (4 changes)
Short interest and volume: Short interest spike became public on 28 Jan 2026
Invivyd had 21.4M shares sold short in the 15 Jan 2026 report, 3.4× the same report last year.
This period
21.4M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
7.1M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+6.0
Same report last year
6.3M
History used
1,218 days
the 15 Jan 2026 report24 earlier reportsnormal: 7.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 17 Feb 2026
Invivyd saw 46 13F filers open a new position in the quarter ended 31 Dec 2025, 5.1× the same quarter last year.
This period
46 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
15.5
Typical spread (median absolute deviation)
5
How far from its usual level
+4.1
Same quarter last year
9
History used
1,553 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 15.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 11 Feb 2026
Invivyd had 22.3M shares sold short in the 30 Jan 2026 report, 3.4× the same report last year.
This period
22.3M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
7.4M
Typical spread (median absolute deviation)
2.0M
How far from its usual level
+4.9
Same report last year
6.6M
History used
1,233 days
the 30 Jan 2026 report24 earlier reportsnormal: 7.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Feb 2026
Invivyd had 22.7M shares sold short in the 13 Feb 2026 report, 2.7× the same report last year.
This period
22.7M (the 13 Feb 2026 report)
Normal report (median of 24 earlier)
7.7M
Typical spread (median absolute deviation)
2.6M
How far from its usual level
+3.8
Same report last year
8.5M
History used
1,247 days
the 13 Feb 2026 report24 earlier reportsnormal: 7.7M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
17 Feb 2026Institutional holdings change
saw 46 13F filers open a new position in the quarter ended 31 Dec 2025, 5.1× the same quarter last year.
Same quarter last year: 9; its normal quarter is 15.5.
See the evidence
This period
46 (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
15.5
Typical spread (median absolute deviation)
5
How far from its usual level
+4.1
Same quarter last year
9
History used
1,553 days
the quarter ended 31 Dec 20258 earlier quartersnormal: 15.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 22.3M shares sold short in the 30 Jan 2026 report, 3.4× the same report last year.
Same report last year: 6.6M; its normal report is 7.4M.
See the evidence
This period
22.3M (the 30 Jan 2026 report)
Normal report (median of 24 earlier)
7.4M
Typical spread (median absolute deviation)
2.0M
How far from its usual level
+4.9
Same report last year
6.6M
History used
1,233 days
the 30 Jan 2026 report24 earlier reportsnormal: 7.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 21.4M shares sold short in the 15 Jan 2026 report, 3.4× the same report last year.
Same report last year: 6.3M; its normal report is 7.1M.
See the evidence
This period
21.4M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
7.1M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+6.0
Same report last year
6.3M
History used
1,218 days
the 15 Jan 2026 report24 earlier reportsnormal: 7.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 35.6M shares sold short in the 31 Dec 2025 report, 8.9× the same report last year.
Same report last year: 4.0M; its normal report is 6.8M.
See the evidence
This period
35.6M (the 31 Dec 2025 report)
Normal report (median of 24 earlier)
6.8M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+12.0
Same report last year
4.0M
History used
1,203 days
the 31 Dec 2025 report24 earlier reportsnormal: 6.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 28.6M shares sold short in the 15 Dec 2025 report, 7.8× the same report last year.
Same report last year: 3.7M; its normal report is 6.6M.
See the evidence
This period
28.6M (the 15 Dec 2025 report)
Normal report (median of 24 earlier)
6.6M
Typical spread (median absolute deviation)
1.7M
How far from its usual level
+8.9
Same report last year
3.7M
History used
1,187 days
the 15 Dec 2025 report24 earlier reportsnormal: 6.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 28.2M shares sold short in the 28 Nov 2025 report, 5.8× the same report last year.
Same report last year: 4.9M; its normal report is 6.6M.
See the evidence
This period
28.2M (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
6.6M
Typical spread (median absolute deviation)
1.7M
How far from its usual level
+8.8
Same report last year
4.9M
History used
1,170 days
the 28 Nov 2025 report24 earlier reportsnormal: 6.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 27.5M shares sold short in the 14 Nov 2025 report, 4.1× the same report last year.
Same report last year: 6.7M; its normal report is 6.6M.
See the evidence
This period
27.5M (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
6.6M
Typical spread (median absolute deviation)
1.5M
How far from its usual level
+9.5
Same report last year
6.7M
History used
1,156 days
the 14 Nov 2025 report24 earlier reportsnormal: 6.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 24.1M shares sold short in the 31 Oct 2025 report, 2.9× the same report last year.
Same report last year: 8.3M; its normal report is 6.6M.
See the evidence
This period
24.1M (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
6.6M
Typical spread (median absolute deviation)
1.5M
How far from its usual level
+7.9
Same report last year
8.3M
History used
1,142 days
the 31 Oct 2025 report24 earlier reportsnormal: 6.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.7M shares sold short in the 15 Oct 2025 report, 2.3× the same report last year.
Same report last year: 7.1M; its normal report is 6.6M.
See the evidence
This period
16.7M (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
6.6M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+5.2
Same report last year
7.1M
History used
1,126 days
the 15 Oct 2025 report24 earlier reportsnormal: 6.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $11.8M for the quarter ended 30 Jun 2025, 5.2× the same quarter last year.
Same quarter last year: $2.3M; its normal quarter is $1.1M.
See the evidence
This period
$11.8M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$1.1M
Typical spread (median absolute deviation)
$1.1M
How far from its usual level
+6.3
Same quarter last year
$2.3M
History used
731 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $1.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $11.3M for the quarter ended 31 Mar 2025, against none in the same quarter last year.
See the evidence
This period
$11.3M (the quarter ended 31 Mar 2025)
Normal quarter (median of 7 earlier)
$0
Typical spread (median absolute deviation)
$0
How far from its usual level
+11.3
Same quarter last year
$0
History used
640 days
the quarter ended 31 Mar 20257 earlier quartersnormal: $0
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 7.4M shares sold short in the 13 Sep 2024 report, 3.5× the same report last year.
Same report last year: 2.1M; its normal report is 2.6M.
See the evidence
This period
7.4M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
2.6M
Typical spread (median absolute deviation)
673K
How far from its usual level
+4.8
Same report last year
2.1M
History used
729 days
the 13 Sep 2024 report24 earlier reportsnormal: 2.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.6M shares sold short in the 30 Aug 2024 report, 3.9× the same report last year.
Same report last year: 1.9M; its normal report is 2.4M.
See the evidence
This period
7.6M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
468K
How far from its usual level
+7.6
Same report last year
1.9M
History used
715 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.9M shares sold short in the 15 Aug 2024 report, 3.3× the same report last year.
Same report last year: 2.4M; its normal report is 2.4M.
See the evidence
This period
7.9M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
415K
How far from its usual level
+9.0
Same report last year
2.4M
History used
700 days
the 15 Aug 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.8M shares sold short in the 31 Jul 2024 report, 3.4× the same report last year.
Same report last year: 2.3M; its normal report is 2.4M.
See the evidence
This period
7.8M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
385K
How far from its usual level
+9.5
Same report last year
2.3M
History used
685 days
the 31 Jul 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.6M shares sold short in the 15 Jul 2024 report, 3.6× the same report last year.
Same report last year: 2.1M; its normal report is 2.3M.
See the evidence
This period
7.6M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
358K
How far from its usual level
+10.0
Same report last year
2.1M
History used
669 days
the 15 Jul 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6410097
11 Jul 2024Short interest and volume change
had 7.1M shares sold short in the 28 Jun 2024 report, 3.2× the same report last year.
Same report last year: 2.2M; its normal report is 2.3M.
See the evidence
This period
7.1M (the 28 Jun 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
277K
How far from its usual level
+11.6
Same report last year
2.2M
History used
652 days
the 28 Jun 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.8M shares sold short in the 14 Jun 2024 report, 2.3× the same report last year.
Same report last year: 2.9M; its normal report is 2.3M.
See the evidence
This period
6.8M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
277K
How far from its usual level
+10.9
Same report last year
2.9M
History used
638 days
the 14 Jun 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 6.9M shares sold short in the 31 May 2024 report, 2.8× the same report last year.
Same report last year: 2.5M; its normal report is 2.3M.
See the evidence
This period
6.9M (the 31 May 2024 report)
Normal report (median of 24 earlier)
2.3M
Typical spread (median absolute deviation)
206K
How far from its usual level
+15.0
Same report last year
2.5M
History used
624 days
the 31 May 2024 report24 earlier reportsnormal: 2.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 91 entries; narrow the window or the kind of data to see older ones.
Not listed: 136 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001832038
Ticker
IVVD
Domain
invivyd.com
Hq location
CT|NEW HAVEN| (1 unverified)
Lobbying client
adagio therapeutics, invivyd, invivyd formerly known as adagio therapeutics